David O'Malley, MD, discusses the activity of the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.
David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at the Ohio State University (OSU) College of Medicine; and director of the Division of Gynecologic Oncology; director of Clinical Research in Gynecologic Oncology; and co-director of the Gynecologic Oncology Phase I Program at The OSU Comprehensive Cancer Center–James, discusses the activity of the investigational antibody-drug conjugate mirvetuximab soravtansine (IMGN853) in ovarian cancer.
Mirvetuximab soravtansine as monotherapy and in combination with bevacizumab (Avastin) has demonstrated clear activity in women with ovarian cancer, says O'Malley.
When looking at mirvetuximab soravtansine alone and in combination, there is a clear benefit in almost all patients, says O'Malley. According to data presented at the 2020 ASCO Virtual Scientific Program, the combination of mirvetuximab soravtansine and bevacizumab elicited an overall response rate of 47% among patients with platinum-agnostic ovarian cancer.
Even patients who do not derive a response from mirvetuximab soravtansine may see a decrease in cancer antigen 125 or tumor burden, which can be sustained over many months, O’Malley concludes.